Investigators had to carry equipment to remote clinics over rugged terrain; one study site was repeatedly robbed; and early on in the trial, some participants fled armed conflict. Sleeping sickness — also known as human African trypanosomiasis — is spread through the bite of tsetse flies carrying parasites , most commonly Trypanosoma brucei gambiense. The organism infects the central nervous system, and patients can experience confusion, daytime sleepiness, night-time insomnia and various psychiatric symptoms, including manic episodes and aggression.
If left untreated, they enter a coma and die. For decades, the only treatment was a toxic arsenic-based drug that killed one in 20 patients. In , researchers introduced a safer option: nifurtimox—eflornithine combination therapy, or NECT, which consists of pills and 14 intravenous infusions. But the need for infusions, along with the spinal tap required to qualify a patient for the treatment, still present obstacles in regions where sterile equipment, electricity and doctors are in short supply.
In , it discovered fexinidazole, a compound that had been shelved by Paris-based pharmaceutical company Sanofi. With the firm's agreement, the DNDi took the drug through clinical trials. Sanofi will soon submit an application for drug approval through the European Medicines Agency, whose sign-off could pave the way for regulators in the Democratic Republic of the Congo. Because it is a simple oral treatment, she suggests that patients might even be treated at home, which would save them and their families the expense of hospital stays.
DNDi researchers and their colleagues are currently working on what they hope will be an even better oral treatment to cure the disease in a single dose, and more reliably than fexinidazole. You can also search for this author in PubMed Google Scholar. Busting the billion-dollar myth: how to slash the cost of drug development Aug Projects set to tackle neglected diseases Jan Neglected diseases fund touted May The Drugs for Neglected Diseases initiative.
Information on Sleeping Sickness. Death will occur. Can African sleeping sickness be prevented? Experts recommend the following: Wear protective clothing, such as long-sleeved shirts and pants.
Tsetse flies can bite through material, so clothing should be made of thick fabric. Wear khaki, olive, or other neutral-colored clothing. Tsetse flies are attracted to bright and dark contrasting colors. Use bed nets when sleeping. Look inside vehicles for tsetse flies before getting into them. Do not ride in the back of jeeps, pickup trucks, or other open vehicles.
Tsetse flies are attracted to the dust created by moving vehicles and animals. Stay away from bushes. During the hottest part of the day, the tsetse fly will rest in bushes. But they will bite if disturbed. When should I call my healthcare provider? Key points African sleeping sickness is a disease caused by a parasite. The only risk factor is travel to parts of Africa where the tsetse fly is found. The only way to prevent the disease is to avoid insect bites. Medicine is available to treat it.
Next steps Tips to help you get the most from a visit to your healthcare provider: Know the reason for your visit and what you want to happen. Before your visit, write down questions you want answered. Bring someone with you to help you ask questions and remember what your provider tells you. At the visit, write down the name of a new diagnosis, and any new medicines, treatments, or tests.
Also write down any new instructions your provider gives you. Know why a new medicine or treatment is prescribed, and how it will help you. Also know what the side effects are. Ask if your condition can be treated in other ways.
Know why a test or procedure is recommended and what the results could mean. During this stage, people develop neuropsychiatric symptoms such as sleep disruption, confusion, lethargy, and convulsions. If left untreated, sleeping sickness is usually fatal. Pre, treatments for stage-2 of the disease were toxic or difficult to administer. The arsenic derivative melarsoprol was developed in In , DND i and partners launched NECT , the first new treatment for sleeping sickness in 25 years; however, it requires specialized hospital administration and trained staff.
At the end of , fexinidazole , an all-oral day treatment that we developed with our partners was recommended by the European Medicines Agency for treatment of both stages of gambiense sleeping sickness.
NECT has been provided free of charge in all 13 countries with recent sleeping sickness cases. From Sanofi will similarly donate supplies of fexinidazole.
WHO has set the target of eliminating sleeping sickness as a public health problem by In order to maintain the current low levels of disease and reach the elimination target, a safe, effective, short-course oral treatment suitable for use in remote settings is needed.
We aim to deliver new oral treatments to cure sleeping sickness to support the sustainable elimination of the disease. In addition to developing the first all-oral treatment for sleeping sickness, we are working on acoziborole, a new single-dose oral drug that could be a critical for sustainable elimination. Find out about our work developing treatments for sleeping sickness. Diagnosing sleeping sickness involves invasive tests to confirm a positive result by the rapid diagnostic tests used for community screening.
Diagnosis requires confirming the presence of the parasite in any body fluid, usually in the blood and lymph system through a microscope. Painful lumbar punctures are used to detect the parasite in spinal fluid, which indicates the advanced stage of the disease.
0コメント